The immune response to viral glycoproteins is often directed against conformation-and/or glycosylationdependent structures; synthetic peptides and bacterially expressed proteins are inadequate probes for the mapping of such epitopes. This report describes a retroviral vector system that presents such native epitopes on chimeric glycoproteins in which protein fragments of interest are fused to the C terminus of the N-terminal domain of the murine leukemia virus surface protein, gp7O. The system was used to express two disulfidebonded domains from gpl20, the surface protein of human immunodeficiency virus type 1 (HIV-1), that include potent neutralization epitopes. The resulting fusion glycoproteins were synthesized at high levels and were efficiently transported and secreted. A fusion protein containing the HXB2 V1IV2 domain was recognized by an HIVIjIB-infected patient serum as well as by 17 of 36 HIV-1 seropositive hemophiliac, homosexual male and intravenous drug user patient sera. Many of these HIV+ human sera reacted with V1IV2 domains from several HIV-1 clones expressed in fusion glycoproteins, indicating the presence of cross-reactive antibodies against epitopes in the V1IV2 domain. Recognition of gp(l-263):Vl/V2HxB2 by the HIVIIIn-infected human patient serum was largely blocked by synthetic peptides matching Vi but not V2 sequences, while recognition of this construct by a broadly cross-reactive hemophiliac patient serum was not blocked by individual Vi or V2 peptides or by mixtures of these peptides. A construct containing the V3 domain of the IIIB strain of HIV-1, gp(l-263):V3HXB2, was recognized by sera from a human and a chimpanzee that had been infected by HIVIIIB but not by sera from hemophiliac patients who had been infected with HIV-1 of MN-like V3 serotype. The reactive sera had significantly higher titers when assayed against gp(1-263):V3HXB2 than when assayed against matching V3 peptides. Immunoprecipitation of this fusion glycoprotein by the human serum was only partially blocked by V3 peptide, indicating that this infected individual produced antibodies against epitopes in V3 that were expressed on the fusion glycoprotein but not by synthetic peptides. These data demonstrated that the chimeric glycoproteins described here effectively present native epitopes present in the V1IV2 and V3 domains of gpl20 and provide efficient methods for detection of antibodies directed against native epitopes in these regions and for characterization of such epitopes.
The immune response to viral glycoproteins is often directed against conformation-and/or glycosylationdependent structures; synthetic peptides and bacterially expressed proteins are inadequate probes for the mapping of such epitopes. This report describes a retroviral vector system that presents such native epitopes on chimeric glycoproteins in which protein fragments of interest are fused to the C terminus of the N-terminal domain of the murine leukemia virus surface protein, gp7O. The system was used to express two disulfidebonded domains from gpl20, the surface protein of human immunodeficiency virus type 1 (HIV-1), that include potent neutralization epitopes. The resulting fusion glycoproteins were synthesized at high levels and were efficiently transported and secreted. A fusion protein containing the HXB2 V1IV2 domain was recognized by an HIVIjIB-infected patient serum as well as by 17 of 36 HIV-1 seropositive hemophiliac, homosexual male and intravenous drug user patient sera. Many of these HIV+ human sera reacted with V1IV2 domains from several HIV-1 clones expressed in fusion glycoproteins, indicating the presence of cross-reactive antibodies against epitopes in the V1IV2 domain. Recognition of gp(l-263):Vl/V2HxB2 by the HIVIIIn-infected human patient serum was largely blocked by synthetic peptides matching Vi but not V2 sequences, while recognition of this construct by a broadly cross-reactive hemophiliac patient serum was not blocked by individual Vi or V2 peptides or by mixtures of these peptides. A construct containing the V3 domain of the IIIB strain of HIV-1, gp(l-263):V3HXB2, was recognized by sera from a human and a chimpanzee that had been infected by HIVIIIB but not by sera from hemophiliac patients who had been infected with HIV-1 of MN-like V3 serotype. The reactive sera had significantly higher titers when assayed against gp(1-263):V3HXB2 than when assayed against matching V3 peptides. Immunoprecipitation of this fusion glycoprotein by the human serum was only partially blocked by V3 peptide, indicating that this infected individual produced antibodies against epitopes in V3 that were expressed on the fusion glycoprotein but not by synthetic peptides. These data demonstrated that the chimeric glycoproteins described here effectively present native epitopes present in the V1IV2 and V3 domains of gpl20 and provide efficient methods for detection of antibodies directed against native epitopes in these regions and for characterization of such epitopes.
Conformation-and glycosylation-dependent epitopes in gpl20, the surface protein of human immunodeficiency virus type 1 (HIV-1), are important targets for the neutralizing response to this virus. Epitopes recognized by antibodies that potently block the binding of gpl20 to its receptor, CD4, are believed to be composed of residues from several separated regions of the molecule that are brought together in the native conformation (33, 45) . The importance of native protein structure to the presentation of epitopes in more localized neutralization targets on gpl20 is becoming clear from recent work. A major cluster of neutralizing epitopes in the V3 domain was identified by analysis of the immune response to HIV-1 with use of synthetic peptide probes, and the immunogenicity of this region has been extensively characterized with such methods (27) . It is now evident that synthetic peptide probes are inadequate for the full characterization of the anti-V3 immune response. The reactivity of natural immune sera with V3 peptides in standard solid-phase assays has been found to be a poor predictor of serum reactivity with the V3 loop in native gpl20 (25) . Furthermore, many anti-V3 monoclonal antibodies (MAbs) have higher affinity for native gpl20 than for synthetic peptides (5) , and a potently neutralizing anti-V3 MAb direct against a conformation-dependent epitope has been described (21, 22) . A number of recent reports have described neutralizing MAbs directed against epitopes in the V2 region, many of which are dependent on protein glycosylation and/or conformation (3, 8, 22, 28, 41, 44, 46) . Unlike the case for CD4 binding site epitopes, the global structure of gpl20 appears not to be necessary for presentation of native epitopes in either the V3 or V2 cluster. Straightforward and sensitive methods for detecting immune responses to these and similar epitopes within complex immune sera would greatly facilitate study of the immune response to infection and vaccination, and molecules expressing such native structures may be more effective as immunogens than are synthetic peptides.
The N-terminal domain of the ecotropic murine leukemia virus (MuLV) surface protein, gp7O, was selected as a carrier protein to express glycopeptide domains from other proteins in order to present native epitopes specified by those domains. A truncation fragment that contains the internally disulfidebonded N-terminal region of gp7O (17) has been shown to retain ecotropic receptor binding activity (7) , indicating that this is an autonomously folding globular domain. Similar fragments are generated by protease digestion at hypersensitive sites following the receptor binding domain (29, 36, 37, GLYCOPEPTIDE EXPRESSION SYSTEM 401 40), suggesting that this region of gp70 is exposed on the intact protein. This domain is proline rich and cysteine free and carries 0-linked glycans (4), all of which are common characteristics of regions with extended conformations that serve as spacer domains in membrane proteins (11) . This linker region of gp70 is hypervariable in length and sequence among ecotropic and other MuLVs (7, 13, 42) and is highly immunogenic in MuLVs (29, 40) and the closely related feline leukemia viruses (6, 30) . A site within this interdomain linker of gp70 was used for fusion to disulfide-bonded domains derived from HIV-1 gp120 that contain targets of neutralizing antibodies. Fusion glycoproteins containing each of two such gpl20 fragments were found to be efficiently made and secreted and to present native epitopes that are seen by natural immune sera.
MATERIALS AND METHODS Construction of vectors. The vector for expression of heterologous glycopeptides in fusion proteins with the N-terminal domain of MuLV gp70, pLRB333, was based on Friend ecotropic MuLV clone FB29 (43) , the complete sequence of which was kindly made available by John Portis. The permuted DNA clone was reconstructed in this laboratory into a colinear two-long-terminal-repeat form with minimal duplicated MuLV sequences. For historical reasons, an SphI-to-Bpul 1021 restriction fragment containing env as well as limited flanking sequences was replaced with the homologous fragment from the Friend ecotropic MuLV isolate clone 57 (32) . To construct the truncation derivative of MuLV env designed to receive heterologous gene fragments, PCR with Vent polymerase (New England Biolabs) was used to generate a DNA fragment in which the sequences between the desired truncation point and a Clal restriction site near the 3' end of env were deleted. By incorporation in the PCR primer, an NheI site otherwise absent from the FB29/clone 57 vector was inserted in frame following the codon for amino acid 263 of gp7O followed by two stop codons and the Clal site. The NheI site results in addition of Ala-Ser to the C terminus of the truncated gp70 sequence.
For insertion of gene fragments into this vector, DNA fragments from specific regions of HIV-1 env were generated by PCR. An in-frame restriction site for NheI at the 5' end and two in-frame stop codons followed by a Clal restriction site at the 3' end were incorporated into the primers. These 
"Sequences are taken from the Human Retroviruses and AIDS data base; for HXB2d, the sequence includes amino acid residues 86 to 179 of gpl20. Signals for N-linkcd glycosylation are underlined; positions of cysteine residues, all of which are fully conserved, are marked by asterisks.
It was obtained as the cyclic form. An MN V3 peptide, ADP 715 (RKRIHIGPGRAFYTTKN), corresponding to the tip of the V3 loop was obtained from the MRC AIDS Reagent Project.
To obtain partially purified V3 fusion glycoprotein for enzyme-linked immunosorbent assay (ELISA), supernatants from 3T3 cells expressing the His, form of gp(1-263):V31iXB2 were dialyzed against phosphate-buffered saline (PBS; pH 8), NaCl was added to 0.5 M, and protein was bound to Ni2+-nitrilotriacetate-Sepharose (Qiagen) in this buffer. gp(1-263):
WtlM32 was eluted with 30 mM imidazole in PBS (pH 7.4) following a 20 mM imidazole wash. The antigen constituted only a small fraction of the Coomassie-staining protein in these preparations (data not shown) but was readily detected by direct ELISAs performed with this material.
ELISAs were performed in TiterTek Immuno-assay plates (Flow Laboratories). Antigens were adsorbed to wells for 60 min in 100 [l of carbonate buffer (pH 9.6), washed with PBS-0.05% Tween, blocked for 90 min with 2% bovine serum albumin (BSA) in PBS, and washed again with PBS-0.05% Tween. Then 100 ()l of serum diluted in PBS was added for 60 min at room temperature, wells were washed with PBS-0.05% Tween, incubated for 60 min with 100 ,ul of alkaline phosphatase-coupled goat anti-human IgG (Zymed) diluted in 2% BSA, and washed in PBS-0.05% Tween, and 100 .I1 of 1-mg/ml p-nitrophenol phosphate in diethanolamine buffer (pH 9.8) was added. A405 was measured between 30 and 60 min after substrate addition. The amount of partially purified gp(1-263):
V3,Il3, used per assay was always sufficient to give at least 75% of the maximum achievable signal. Peptides were used at 100 ng per well; assays were insensitive to increased amounts of peptide. Background A405 reactivity in wells lacking antigen was subtracted from each of the datum points presented.
RESULTS
Synthesis and processing of fusion glycoproteins containing sequences from HIV-1 gpl20. Gene constructs were prepared to express the VI/V2 and V3 domains of HXB2 gpI20 in fusion glycoproteins with the N-terminal domain of MuLV gp7O. The sequences and disulfide bonding patterns of the resulting chimeric proteins are shown diagrammatically in Fig. 1, based on the published secondary structures of gp7O (17) and gpl20 (16) . The selected fragments of gpl2O corresponded to distinct disulfide-bonded domains of the protein containing hypervariable regions and neighboring conserved sequences. The V1/V2 domain was expressed as a 94-amino-acid fragment (Fig. IA) that includes three disulfide bonds. Two of these disulfide bonds generate the VI and V2 variable loops separated by a short stretch of conserved sequence, and the third disulfide bond generates an arm of conserved flanking sequences. This expressed sequence included six signals for N-linked glycosylation, all of which have been reported to be utilized (15, 16) and one of which (attached to Asn-156) was found to be necessary for viral growth in cell culture (15) . The 46-aminoacid V3 domain fragment (Fig. IB) contained the disulfidebonded loop itself and five flanking amino acids N and C terminal to the defining Cys residues. It included three signals for N-linked glycosylation, one within the V3 loop and one on each flank, all of which have been reported to be utilized (15, 16) and none of which were found to be required for viral growth in cell culture (15) .
The level of expression and efficiency of processing of the V1/V2 fusion glycoprotein was compared with that of gp(1-263), the N-terminal truncation product of gp7O that served as the fusion partner in these constructs, in pulse-chase experiments. The analysis of gp(1-263) was performed in cells that coexpressed a wild-type MuLV env, allowing comparison of the synthesis and processing of the truncation fragment with that of normal e;zv proteins. A hyperimmune antiserum to gp7O was used to immunoprecipitate products containing gp7O epitopes. gp(1-263) was synthesized at a high level and was efficiently and rapidly secreted ( Fig. 2A) . At the end of a 30-min pulse-label, gPr8O, the primary translation product of the wild-type env, and a 32-kDa form of gp(1 -263) were seen in cell lysates. After a 1-h chase, more than 90% of gp(I-263) was found in the culture supernatant. In contrast, while the majority of gPr8O had been converted to mature gp7O at this time, only a small fraction of the gp7O had been released from the cells. This difference in the rate of secretion is probably due to the fact that the truncation fragment is a soluble protein that enters the secretion pathway and is therefore rapidly released from the cell, while gp7O is retained on cellular membranes by interaction with the viral TM protein and its release into the supernatant requires either shedding from the cell surface or incorporation into virions. Note that almost all of the gp(1-263) was processed and secreted. In contrast, only a relatively small fraction of gPr8O was ever processed to gp7O; most of the precursor appeared to be degraded intracellularly. Figure 2B presents a pulse-chase analysis of the processing and secretion of the V1/V2 fusion glycoprotein. The 59-kDa primary translation product of gp(l-263):Vl/V2HXB2 was seen at the end of the 30-min pulse-label. After 1 h of chase, fusion glycoprotein started appearing in the supernatant, and by 4 h, almost all of the gp(1-263):Vl/V2HXB2 had been secreted. The secreted material was larger and more diffuse than the intracellular precursor. This was presumably due to processing of the N-linked glycans into larger complex forms in the Golgi apparatus, since enzymatic removal of N-linked glycans yielded a single well-defined species on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (data not shown).
The increase in apparent size for the secreted form of gp(1-263):Vl/V2HXB2, which carries eight N-linked glycans that may all be processed to complex forms, was much greater than for the secreted form of gp(1-263) ( Fig. 2A) Fig. 3A and B and data not shown).
The recognition of gp(1-263):Vl/V2HXB2 by sera from individuals exposed to random HIV isolates suggested that these sera recognized conserved epitopes presented by the fusion glycoprotein. To determine whether this was the case, fusion glycoproteins containing the V1/V2 domains from the MN, JR-CSF, JR-FL, SF2, and NL4-3 HIV-1 isolates were produced. The sequences of the V1/V2 domains are quite variable among these five isolates and HXB2d (Table 1) . The six gp(1-263):VI/V2 fusion glycoproteins were immunoprecipitated with a selection of human sera (Fig. 3) . The HIVIIIBspecific laboratory worker serum reacted strongly with gp(1-263):Vl/V2HXI32 and gp(I-263):Vl/V2NL4-3, the two fusion constructs bearing sequences from HIVIIIB isolates, with a preference for the HXB2 construct, and reacted more weakly with gp(1-263):V1/V2MN (Fig. 3A, lane 9; Fig. 3B, lane 11) .
This serum did not react with any of the other constructs, indicating that its anti-VI/V2 response was largely type specific. Eighteen HIV+ human sera from New York City hemophiliac patients and homosexual men were tested for the ability to recognize these V1/V2 fusion glycoproteins; seven precipitated between three and five of the six V1/V2 fusion glycoproteins, while the rest of these sera did not recognize any of the fusion glycoproteins at a level clearly above the background seen with HIV-human sera. gp(1-263):V1/V2SF2 was the only construct not immunoprecipitated by any of these sera.
To determine whether these responses were directed against specific linear epitopes, selected sera were examined for reactivity with synthetic peptides matching the HIV-1 sequence expressed in gp(1-263):V1/V2HxB2. A series of nine 20-mer oligopeptides with 10-amino-acid overlaps corresponding to residues 82 to 181 of HXB2 gpl20 were tested for reactivity in solid-phase ELISAs. The HIVIJIB-infected human serum, two highly cross-reactive hemophiliac patient sera (used in lanes 1 and 8 of Fig. 3A) , and two nonreactive hemophiliac patient sera (used in lanes 3 and 7 of Fig. 3A) were examined. The HIVIIIB-infected human serum reacted strongly only with two overlapping peptides matching VI loop sequences, ADP 740.11 (amino acids 102 to 121) and ADP 740.12 (amino acids 112 to 131) (data not shown). On the other hand, all four of the hemophiliac patient sera tested reacted strongly and specifically with a peptide corresponding to sequences extending from the C terminus of VI into the N-terminal region of V2, ADP 740.13 (amino acids 122 to 141), and less strongly with the next overlapping peptide, ADP 740.14 (amino acids 132 to 151); one of these sera also reacted with ADP 740.11, the amino acid 102-121 Vl region peptide (data not shown). Since the lack of correlation between reactivity of these hemophiliac patient sera with V1/V2 domain peptides by ELISA and with V1/V2 fusion glycoproteins by immunoprecipitation was surprising, the ELISA reactivities of additional sera were tested against a larger set of peptides containing sequences corresponding to this particular region from several HIV-1 strains. These assays used ADP 740. 13 (Fig. 4) . These data appeared to map the peptide ELISA reactivity to amino acids 135 to 141 (IRGKVQK), the sequence common to all of the reactive peptides. peptides was not a predictor of activity against V1/V2 fusion glycoproteins.
The discrepancies between the peptide reactivity and recognition of V1/V2 fusion glycoproteins could mean that the two assays detect completely different sets of antibodies present in these HIV+ sera or that the peptide ELISA has greater sensitivity and therefore detects reactive antibodies in a larger number of sera. This issue was investigated by determining the ability of one of the strongly cross-reactive hemophiliac patient sera to precipitate gp(I-263):VI/V2HXB2 in the presence of a large molar excess of a mixture of the overlapping 20-mer peptides spanning amino acids 82 through 181 of the HXB2 sequence. This mixture of peptides effectively blocked precipitation by the HIV,IIB-infected patient serum (Fig. 5) , as did each of the VI peptides ADP 740.11 and ADP 740.12 by themselves (data not shown), consistent with the specificity of this serum for these peptides by ELISA. However, the peptide mixture was unable to significantly inhibit precipitation by the cross-reactive hemophiliac patient serum (Fig. 5) . This result suggested that the precipitating anti-V1/V2 antibodies in the cross-reactive sera were not the same as the antibodies reacting with amino acids 135 to 141 detected by ELISA. Presumably the cross-reactive anti-VIV2 activity in these sera is directed against native epitopes that require a more accurate presentation of gpl2O structure than was achieved by the synthetic peptides. The nature and significance of the anti-peptide ELISA reactivity seen with the New York City HIV+ sera is not clear.
Reactivity of HIV+ sera with gp(1-263):V3HXB2. The fusion protein expressing the HXB2 V3 sequence, gp(l-263):V3HXB2, was specifically precipitated by the sera from the HIVIIIBinfected patient and chimpanzees. None of the hemophiliac patient sera precipitated this fusion glycoprotein (Fig. 6 and data not shown), consistent with peptide ELISA data that showed a strong preference of these patient sera for MNlike V3 sequences (data not shown). The reactivities of the HIVIIIB-infected patient and chimpanzee sera to gp(l-263): V3HXB32 were compared with the reactivities of these sera to two synthetic peptides corresponding to HXB2 V3 loop sequences in solid-phase ELISAs. The titers of the sera (serum dilution giving 50% maximal reaction) were determined against gp(I-263):V3t1XB2, against a synthetic linear peptide containing the complete V3 domain sequence present between the defining cysteines, and against a purportedly cyclic peptide that contained the entire V3 domain sequence, including the Cys residues that form the loop (Fig. 7) . The human serum possessed a sevenfold-higher titer against the fusion glycoprotein than against either of the peptides. For the chimpanzee serum, the titer against gp(l-263):V3HXB2 was threefold higher than against the cyclic peptide and sixfold higher than against the linear peptide. As shown in Fig. 8 , the cyclic V3 peptide partially blocked immunoprecipitation of gp(1-263):V3Hx132 by the serum from the HIVIIIB-infected human patient and fully blocked immunoprecipitation by the serum from the HIVIJIBinfected chimpanzee, while having no effect on immunoprecipitation by the anti-gp7O serum. Since the majority of the anti-V3 precipitating activity in these sera was blocked by the matching cyclic peptide, this peptide must have presented the epitopes seen by most of the anti-V3 antibodies in these sera. These data indicated that the anti-V3 antibodies in this chimpanzee serum had a higher affinity for gp(1-263):V3HXB2 than for the homologous V3 peptide but contained little or no antibody against epitopes that were not presented by the cyclic V3 peptide. However, the residual precipitation by the serum from the HIV111B-infected human patient in the presence of the cyclic V3 peptide suggested that this serum possessed anti-V3 antibodies that reacted with epitopes not effectively presented by the peptide. were significantly higher on gp(I-263):V3HXB2 than on homologous V3 peptides; for the laboratory worker serum, the difference was about sevenfold. Furthermore, although immunoprecipitation of gp(I-263):V3HXB2 by the chimpanzee serum was fully blocked by excess cyclic V3 peptide, immunoprecipitation by the human serum was only partially blocked by this peptide. These data indicated that most anti-V3 antibodies present in these immune sera had higher affinity for the fusion glycoprotein than for V3 peptides and that this human serum recognized epitopes that were presented by the V3 fusion glycoprotein but not by V3 peptides. These data are consistent with reports showing that a serum sample from this patient has a 10-fold higher titer on native gpl20 than on denatured protein (26) and that a large fraction of its total gpl2O reactivity is with V3 epitopes (25) . Little or no reactivity with this construct was found in a screen of approximately 30 HIV+ hemophiliac patient sera of MN-like V3 serotype as determined with V3 peptides (data not shown). On the other hand, many of these sera did react with a fusion glycoprotein expressing the MN-like V3 loop from JR-CSF (data not shown). These results indicated that V3 fusion glycoproteins detected a largely type-specific response to V3 epitopes, as do V3 peptides, and suggested that reactivity with V3 fusion glycoproteins can be used to assay the type specificity and magnitude of anti-V3 responses.
The gp(1-263):V1/V211X132 fusion glycoprotein was recognized by the HIVIIIB-infected human and chimpanzee sera. In addition, 17 of 36 HIV+ sera from hemophiliac, homosexual male, and intravenous drug user patients recognized this fusion glycoprotein. Since the hemophiliac patients were exposed to viruses with an MN-like V3 domain, the anti-VI/V2 reactivities of these sera were likely to be cross-reactive responses. This expectation was confirmed by the finding that hemophiliac patient and homosexual male sera that were reactive with gp(1 -263):Vl/V2HXB2 also precipitated fusion glycoproteins bearing V1/V2 sequences from other HIV-1 isolates. As many as five of the six distinct V1/V2 domains examined were recognized by many of these sera. The only sequence not recognized by any of these sera was that of SF2, suggesting that SF2 gpl20 represented a distinct V1/V2 serotype. (28) . These geographical preferences suggest the possibility of strain-specific effects but are difficult to rationalize with a nonspecific charge interaction hypothesis. Furthermore, the fact that a number of potent neutralizing rat MAbs were shown to recognize the HXB2 132-141 V2 peptide (22) indicates that this region contains functional epitopes. The discrepancies between ELISA and immunoprecipitation data may reflect detection of low-affinity antibodies in solidphase formats (25) . Taken together, these data indicate that caution is called for in the interpretation of ELISA results with peptides containing the N-terminal sequence of V2.
Although peptide reactivity data did not allow localization of the epitope(s) seen by the cross-reactive sera within the sequences expressed by the V1/V2 fusion glycoproteins, comparison of the expressed sequences that were and were not recognized suggests that the critical region is likely to be within V2. The flanking conserved sequences are retained in the SF2 construct that is not recognized by any of these sera, and the MN sequence that is recognized is much more divergent in VI than is the SF2 sequence. The SF2 sequence is the most divergent sequence in the relatively conserved N-terminal region of V2 and in the highly variable C-terminal region of V2, both of which have been shown to be important for the epitopes of neutralizing MAbs (22, 25, 44) . The lack of recognition of the SF2 construct by these sera indicates that these reactivities represent epitope-specific complementarity determining region-mediated recognition by the antibodies rather than the VH3-mediated binding of antibodies that has recently been described for SF2 gpl20 (2) .
The nature of the native cross-reactive epitopes in the V1!V2 domain recognized by the human sera described in this study is of interest. Analyses of gp(l-263):Vl/V2HXB2 with appropriate MAbs demonstrated that this fusion glycoprotein presents both conformation-and glycan-dependent epitopes (22, 41, 47a) . One or both of these classes of epitopes are likely to be the basis of the preference of immune sera for fusion glycoprotein over synthetic peptide. The fact that many MAbs recognizing epitopes in V2 neutralize viral infectivity (3, 8, 22, 25, 46, 46a) suggests that the anti-V1/V2 antibodies in these sera may also have neutralizing activity. Experiments to characterize the V1/V2 epitopes seen by the cross-reactive human sera and to analyze the functional activities of human antibodies against these epitopes are in progress. The work described here demonstrated expression of epitopes by both the V1/V2 and V3 fusion glycoproteins that were not presented by synthetic peptides. Fusion glycoproteins expressing native epitopes from specific regions of gpl20 can be used to monitor antibodies that have not previously been resolved in analyses of human sera; whether any such humoral responses correlate with protection against infection by HIV-1 or progression to AIDS needs to be determined. If so, these fusion glycoproteins would provide an important tool for the evaluation of HIV vaccine trials and could themselves prove to be effective immunogens for inducing such antibodies.
